Oncology/neurology approach to ICI toxicity
| Step | ESMO guideline6 | Neurology input |
| 1 | Diagnosis and grading | Syndrome classification/neuroanatomical localisation |
| 2 | Rule out differential diagnoses and pre-immunosuppression work-up | Neurological differential diagnosis |
| 3 | Select appropriate immunosuppression strategy for grade 2+ events | Treatment guidance from analogous neuroinflammatory syndromes |
| 4 | Active evaluation at 72 hours to adapt treatment | Efficacy monitoring |
ESMO, European Society for Medical Oncology; ICI, immune checkpoint inhibitor.